###### Key messages

1.  The strength of this systematic review was the large number of studies included with over half a million total participants.

2.  Another strength was that we were able to evaluate the effect of different major bleeding definitions and its impact on risk of mortality and major adverse cardiovascular events.

3.  This systematic review had the limitation that studies included varied in antithrombotic and antiplatelet regimes after PCI procedure.

4.  Another limitation was that the systematic review was unable evaluate whether the subsequent mortality was directly related to the bleed.

Introduction {#s1}
============

Advances in antithrombotic therapy have improved the outcomes of patients undergoing percutaneous coronary intervention (PCI) through the reduction of ischaemic events at the expense of increased procedure-related bleeding complications. Major bleeding events in contemporary PCI are significant, with 30-day bleeding event rates reported between 0.7% and 1.1% in elective,[@R1] 0.6% and 4.7%[@R3] in non-ST-elevation myocardial infarction (NSTEMI) and 0.9% and 8.9% in ST-elevation myocardial infarction (STEMI)[@R3] [@R4] [@R7] [@R8] depending on the definition used.

There are currently around 10 different definitions of major bleeding used in trials and registries of patients undergoing PCI[@R9] [@R10] and these definitions include various clinical events, such as blood transfusion or retroperitoneal haemorrhage, laboratory parameters, such as differing values of haemoglobin decreases, and clinical outcomes such as mortality[@R9] resulting in significant differences in bleeding event recording across clinical trials thereby making comparisons between therapeutic strategies difficult. Furthermore, the incidence of major bleeding varies depending on definition used. In one study, the RIVAL non-coronary artery bypass graft (non-CABG) related major bleeding occurred in 0.87% in the STEMI cohort and 0.57% in the NSTEMI group, while if an ACUITY major bleeding definition was used, major bleeding occurred in 3.1% in the STEMI group and 2.26% in the NSTEMI group, respectively.

Major periprocedural bleeding complications following PCI are predictors of mortality and major adverse cardiovascular events (MACEs),[@R11] with up to 12.1% of all in-hospital mortality after PCI in the National Cardiovascular Data Registry\'s CathPCI Registry related to bleeding complications.[@R14] In contrast, other studies have suggested that although bleeding may be causally related to adverse outcomes in some patients in the real-world setting, it is often merely a marker for patients at higher risk for adverse outcomes.[@R15] [@R16]

Some prior studies that have reported on the prognostic impact of major bleeds have not accounted for differences in baseline covariates such as age, syndrome of presentation and comorbidities that would themselves impact on MACEs and mortality outcomes.[@R17] In contrast, while other studies have adjusted for baseline covariates, different definitions of major bleeding such as TIMI,[@R2] [@R11] [@R22] [@R23] GUSTO,[@R20] [@R24] STEEPLE[@R20] [@R25] and BARC[@R23] have been used, which have been shown to have differential impacts on mortality/MACEs outcomes.[@R20] [@R23] [@R26] Furthermore, the timing of bleeding from index PCI procedures included in such studies has varied from 48 h,[@R25] been limited to those that occur in hospital,[@R23] [@R27] to 30 days[@R2] [@R28] with impact on mortality and MACEs outcomes studied at different time points such as 30 days,[@R8] [@R24] [@R28] 6 months[@R24] [@R27] or 1 year.[@R2] [@R22] [@R23] [@R25]

Until today, there has not been a systematic review or meta-analysis previously published studying the prognostic impact of periprocedural major bleeding events on mortality and MACEs outcomes following PCI. We have therefore undertaken a meta-analysis to systematically study the impact of major bleeding following PCI on mortality and MACEs outcomes. In this meta-analysis, we provide an overview of the cohorts evaluating the rates of major bleeding events and systematically study the differences in the prognostic impact of different bleeding definitions and the relationship between major bleeding and clinical events at different time points.

Methods {#s2}
=======

Eligibility criteria {#s2a}
--------------------

We selected studies of patients who underwent PCI that reported on mortality or cardiovascular events among patients with and without major bleeding events. There was no restriction based on study design, definition of major bleeding or the indication for PCI or its status as an urgent or elective procedure. We excluded studies that did not report on categories of major bleeding and those that did not report either mortality or MACEs.

Search strategy {#s2b}
---------------

A search of EMBASE (1974 to January 2014) and MEDLINE (1946 to January 2014) was conducted on OvidSP. The search terms are shown in online supplementary figure S1. We did not use any language restrictions. We checked the bibliographies of included studies and relevant review articles found on the search for additional relevant articles.

Study selection and data extraction {#s2c}
-----------------------------------

Two reviewers (CSK and YKL) checked all titles and abstracts for studies that could potentially meet the inclusion criteria. We retrieved full reports of these potentially eligible studies and independently extracted data on study design, participant characteristics, interventions used, major bleeding events, follow-up, outcome events and methods of ascertaining measured clinical events on to a preformatted spreadsheet. Any discrepancies between the two reviewers were resolved by consensus after consulting a third reviewer (MAM).

Quality assessment {#s2d}
------------------

Risk of bias was assessed by considering four different areas: ascertainment of major bleeding events, ascertainment of outcome events, extent of loss to follow-up and the use of adjustment for confounders in the analysis. We also assess for publication bias using funnel plots when there were \>10 studies available in the meta-analysis and there was no evidence of substantial statistical heterogeneity.[@R29]

Data analysis {#s2e}
-------------

We used RevMan V.5.1.7 (Nordic Cochrane Centre) to do random effects meta-analysis using the inverse variance methods for pooled ORs. We assumed similarity between the OR and other relative measures such as relative risk, rate ratios or HRs because cardiovascular events and death were rare events.[@R30] The analysis was stratified based on whether the results had considered the effect of potential confounders through adjustments or propensity-matched cohorts or not. In order to reduce the risk of bias from confounding so that we have a more reliable estimate of the independent effect of bleeding on prognosis, we appraised studies with multivariate adjustments or propensity-matched cohorts separately from studies with crude or unadjusted results. We used adjusted or propensity-matched risk estimates where available. For datasets reporting multiple time points, we took the earliest time point for the primary analysis. Any later time points were subsequently analysed in the separate Forest plots stratified according to timing of outcome assessment. Where there were multiple definitions of major bleeding we choose to use the results for TIMI major bleeding.

We planned for three analyses. The primary analysis was the pooled adjusted and unadjusted risk of mortality with and without major bleed. The secondary analysis was the unadjusted and adjusted risk of MACEs with and without major bleed. In a post hoc sensitivity analysis, we conducted a pooled analysis after excluding studies where it was clear that only some (and not all) of the participants had undergone PCI.

Statistical heterogeneity {#s2f}
-------------------------

We used the I^2^ statistic to assess statistical heterogeneity. I^2^ Values of 30--60% represent moderate levels of heterogeneity.[@R31]

Results {#s3}
=======

Study selection {#s3a}
---------------

The process of selection of studies is shown in online supplementary figure S1. We retrieved 42 relevant studies of patients that underwent PCI (total number of participants 533 333), which evaluated the risk of adverse events with and without major bleeding.[@R2] [@R8] [@R11] [@R14] [@R17] [@R27] [@R28] [@R32] The number of participants in each study ranged from 352 to 280 390 and the number of major bleeding events was 66 277 (37 studies, 15.3%). A total of 40 studies evaluated mortality as an outcome and 11 studies reported on MACEs.

Description of studies included {#s3b}
-------------------------------

The study designs, date of study, country of origin and indication for PCI is shown in [table 1](#OPENHRT2013000021TB1){ref-type="table"}. There were 12 studies (149 650 participants), which were post hoc analyses of randomised controlled trials and 1 matched observational study (280 390 participants). Of the studies that reported number of centres, there were more multicentre studies than single centre studies (n=17 and n=13). The age and gender of participants along with the antiplatelet and anticoagulant regimes used is shown in online supplementary table S1.

###### 

Study design, year of study, country of origin and participant inclusion criteria

  Study ID                             Design                      Date of study                    Number of centres   Country           Inclusion criteria
  ------------------------------------ --------------------------- -------------------------------- ------------------- ----------------- --------------------------------------------------------------------------------------------------
  Amlani *et al* [@R32]                Prospective cohort          May 2003 to July 2007            Single centre       Canada            Patients with STEMI
  Ariza-Sole *et al* [@R33]            Prospective cohort          October 2009 to April 2012       Single centre       Spain             Patients with STEMI
  Barthélémy *et al* [@R20]            Prospective cohort          NA                               Single centre       France            Patients in E-Paris Registry with STEMI and PCI
  Bertrand *et al* [@R34]              Post hoc analysis of RCT    October 2003 to April 2005       Single centre       Canada            Patients in EASY trial with PCI without STEMI
  Boden *et al* [@R35]                 Cohort                      NA                               NA                  The Netherlands   Patients with STEMI and PCI
  Budaj *et al* [@R36]                 Post hoc analysis of RCT    NA                               Multicentre         International     Patients with NSTEMI ACS. Note that only 64--79% had PCI
  Cayla *et al* [@R18]                 Post hoc analysis of RCT    NA                               Multicentre         France            Patients in ABOARD trial with NSTEMI and PCI
  Cayla *et al* [@R37]                 Post hoc analysis of RCT    NA                               Multicentre         International     Patients in ATOLL study with STEMI and PCI
  Chhatriwalla *et al* [@R14]          Matched cohort              2004 to 2011                     Multicentre         USA               Patients in the CathPCI Registry
  Correia *et al* [@R38]               Cohort                      August 2007 to December 2010     Multicentre         Brazil            Patients with ACS. Note that only 76--90% had coronary angiogram
  Eikelboom *et al* [@R28]             Post hoc analysis of RCTs   NA                               Multicentre         International     Patients in OASIS 1 and 2 and CURE who had ACS. Note that only 10--11% had PCI/stent/atherectomy
  Fuchs *et al* [@R21]                 Prospective cohort          January 2001 to June 2005        Single centre       Israel            Patients with STEMI and PCI
  Gitt *et al* [@R39]                  Cohort                      October 2006 to October 2008     Multicentre         International     Patients with ACS. Note that only 65--82% had primary/rescue PCI
  Giugliano *et al* [@R8]              Post hoc analysis of RCT    NA                               Multicentre         International     Patients in ExTRACT-TIMI 25 trial where patients received fibrinolysis
  Hermanides *et al* [@R22]            Prospective cohort          January 1991 to December 2004    Single centre       The Netherlands   Patients with STEMI and PCI
  Kaul *et al* [@R40]                  Post hoc analysis of RCT    May 2004 to August 2008          Multicentre         International     Patients with NSTEMI
  Kikkert *et al* [@R41]               Prospective cohort          January 2003 to July 2008        Single centre       The Netherlands   Patients with STEMI and PCI
  Kinnaird *et al* [@R11]              Retrospective cohort        1991 to 2000                     NA                  USA               Patients who underwent PCI
  Le May *et al* [@R42]                Cohort                      May 2005 to July 2010            NA                  Canada            Patients with STEMI and PCI
  Lee *et al* [@R43]                   Prospective cohort          February 2003 to March 2006      NA                  Korea             Patients with PCI with DES
  Lemesle *et al* [@R27]               Cohort                      January 2000 to December 2007    Single centre       USA               Patients ≥80 years of age with PCI
  Lindsey *et al* [@R44]               Prospective cohort          July 2004 to January 2006        Multicentre         USA               Patients in EVENT registry with PCI
  Lopes *et al* [@R45]                 Retrospective cohort        November 2001 to December 2006   Multicentre         USA               Patients in CRUSADES registry and subset with PCI
  Matic *et al* [@R46]                 Cohort                      August 2009 to December 2012     NA                  Serbia            Patients with STEMI and PCI
  Matic *et al* [@R47]                 Cohort                      August 2009 to December 2010     NA                  Serbia            Patients with STEMI and PCI
  Matic *et al* [@R48]                 Prospective cohort          August 2009 to December 2010     NA                  Serbia            Patients with STEMI and PCI
  Mehran *et al* [@R2]                 Post hoc analysis of RCTs   NA                               Multicentre         International     Patients in REPLACE-2, ACUITY and HORIZONS-AMI trial with PCI
  Montalescot *et al* [@R25]           Post hoc analysis of RCT    December 2005 to December 2006   Multicentre         International     Patients in STEEPLE trial who underwent elective PCI
  Mrdovic *et al* [@R49]               Cohort                      February 2006 to December 2009   Single centre       Serbia            Patients with STEMI and PCI
  Musumeci *et al* [@R50]              Cohort                      June 2005 to June 2008           Multicentre         Italy             Patients with PCI and DES
  Ndrepepa *et al* [@R17]              Post hoc analysis of RCT    September 2005 to January 2008   NA                  Germany           Patients in ISAR-REACT-3 trial with PCI
  Ndrepepa *et al* [@R23]              Post hoc analysis of RCT    NA                               NA                  Germany           Patients in ISAR-REACT, ISAR-SWEET, ISAR-SMART and ISAR-REACT-2 trials with PCI
  Pierre-Louis *et al* [@R51]          Cohort                      NA                               NA                  USA               Patients with ACS and PCI
  Pilgrim and Wenaweser [@R52]         Cohort                      May 2002 to December 2005        Single centre       Switzerland       Patients with PCI
  Polanska-Skrzypczyk *et al* [@R53]   Prospective cohort          February 2001 to October 2002    Single centre       Poland            Patients with STEMI and PCI
  Poludasu *et al* [@R54]              Prospective cohort          July 2001 to May 2010            Multicentre         USA               Patient with PCI
  Rao *et al* [@R24]                   Post hoc analysis of RCTs   NA                               Multicentre         International     Patients in GUSTO IIb, PURSUIT and PARAGON A/B. Note that only 11--30% had PCI
  Rossini *et al* [@R55]               Cohort                      NA                               NA                  USA               Patients with PCI and DES
  Urban *et al* [@R56]                 Prospective cohort          May 2006 to April 2008           Multicentre         International     Patients in e-SELECT registry with PCI and DES
  Valente *et al* [@R19]               Prospective cohort          January 2004 to December 2008    Single centre       Italy             Patients in Intensive Cardiac Care Florence STEMI Registry who had STEMI and PCI
  Yoon *et al* [@R57]                  Cohort                      NA                               NA                  Korea             Patients in IRS DES registry with PCI and DES
  Zheng *et al* [@R58]                 Retrospective cohort        January 2004 to January 2008     Single centre       China             Patients with elective or urgent PCI

ACS, acute coronary syndromes; DES, drug-eluting stent; NA, not applicable; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; RCT, randomised controlled trial; STEMI, ST-elevation myocardial infarction.

[Table 2](#OPENHRT2013000021TB2){ref-type="table"} shows the timing of major bleeding, definition of major bleeding used in the individual studies and the incidence of major bleeding in each study. While many of the studies did not report when assessment for major bleeding took place (n=15), 15 of the studies clearly stated that they evaluated in-hospital major bleeding. The definitions of major bleeding also varied among the included studies and formal definitions of major bleeding included TIMI, GUSTO, STEEPLE, HORIZON-AMI, CRUSADE, BARC and REPLACE-2 definitions. These definitions are summarised in online supplementary table S2. Follow-up of patients in the studies included in this analysis varied from 48 h to more than 3 years. The impact of major bleeding on clinical outcomes was adjusted for baseline covariates in 22 studies (490 699 participants) while in 20 studies (42 634 participants) only unadjusted outcomes were reported.

###### 

Timing of bleeding, definition of major bleeding and follow-up

  Study ID                             Timing of bleeding                  Major/severe bleeding criteria                                                                                                                                                                                                                                                                      Number of participants in bleeding group   Number of participants in control group   Follow-up
  ------------------------------------ ----------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ----------------------------------------- ------------------------------------
  Amlani *et al* [@R32]                Within 30 days                      Haemoglobin drop ≥5 g/dL, intracranial haemorrhage, bleeding requiring surgery or blood transfusion of at least 2 units                                                                                                                                                                             152 (67 had PCI)                           1237 (566 had PCI)                        30 days
  Ariza-Sole *et al* [@R33]            In-hospital                         CRUSADE                                                                                                                                                                                                                                                                                             33                                         1031                                      Mean follow-up 344 days
  Barthélémy *et al* [@R20]            In-hospital                         TIMI, GUSTO, STEEPLE                                                                                                                                                                                                                                                                                Total 671                                  NA                                        1 year
  Bertrand *et al* [@R34]              Unclear                             REPLACE-2                                                                                                                                                                                                                                                                                           19                                         1329                                      30 days, 6 months, 1 year
  Boden *et al* [@R35]                 In-hospital                         CRUSADE                                                                                                                                                                                                                                                                                             203                                        762                                       1 year
  Budaj *et al* [@R36]                 Up to 180 days                      ESSENCE                                                                                                                                                                                                                                                                                             771 (30 days), 937 (180 days)              18 851 (30 days), 18 851(180 days)        180 days
  Cayla *et al* [@R18]                 30 days                             STEEPLE                                                                                                                                                                                                                                                                                             19                                         333                                       30 days
  Cayla *et al* [@R37]                 30 days                             STEEPLE                                                                                                                                                                                                                                                                                             42                                         868                                       30 days
  Chhatriwalla *et al* [@R14]          In-hospital                         CathPCI Registry definition                                                                                                                                                                                                                                                                         56 078                                     224 312                                   In-hospital
  Correia *et al* [@R38]               In-hospital                         BARC type 3 or 5                                                                                                                                                                                                                                                                                    29                                         426                                       In-hospital
  Eikelboom *et al* [@R28]             Within 30 days                      Bleeding that was significantly disabling, bleeding requiring transfusion of ≥2 units of packed cells or bleeding that was life threatening                                                                                                                                                         783                                        3363                                      30-day mortality
  Fuchs *et al* [@R21]                 Unclear                             TIMI                                                                                                                                                                                                                                                                                                27                                         804                                       30 days and 6 months
  Gitt *et al* [@R39]                  In-hospital                         Drop in haemoglobin of \>5 g/dL or haematocrit of \>15%                                                                                                                                                                                                                                             281                                        8451                                      In-hospital
  Giugliano *et al* [@R8]              Up to day 8                         TIMI                                                                                                                                                                                                                                                                                                309                                        20 014                                    30 days
  Hermanides *et al* [@R22]            48 h                                TIMI                                                                                                                                                                                                                                                                                                80                                         4371                                      30 days and 1 year
  Kaul *et al* [@R40]                  Up to 120 h after randomisation     GUSTO                                                                                                                                                                                                                                                                                               598                                        8808                                      30 days
  Kikkert *et al* [@R41]               Unclear                             TIMI                                                                                                                                                                                                                                                                                                35                                         331                                       1--30 days
  Kinnaird *et al* [@R11]              Unclear                             TIMI                                                                                                                                                                                                                                                                                                588                                        8992                                      In-hospital
  Le May *et al* [@R42]                Unclear                             TIMI                                                                                                                                                                                                                                                                                                91                                         1941                                      6 months
  Lee *et al* [@R43]                   Median 1366 days                    STEEPLE                                                                                                                                                                                                                                                                                             148                                        3022                                      Median 1366 days
  Lemesle *et al* [@R27]               In-hospital                         Decrease in haematocrit of ≥15% and/or the occurrence of a major haematoma/gastrointestinal bleeding/intracerebral bleeding                                                                                                                                                                         127                                        2639                                      6 months
  Lindsey *et al* [@R44]               In-hospital                         TIMI                                                                                                                                                                                                                                                                                                180                                        5781                                      1 year
  Lopes *et al* [@R45]                 In-hospital                         CRUSADE                                                                                                                                                                                                                                                                                             3902                                       28 993                                    30 days, 1 year, 3 year, \>3 years
  Matic *et al* [@R46]                 Unclear                             GUSTO                                                                                                                                                                                                                                                                                               32                                         738                                       In-hospital
  Matic *et al* [@R47]                 Unclear                             HORIZONS-AMI                                                                                                                                                                                                                                                                                        88                                         1154                                      30 day
  Matic *et al* [@R48]                 Unclear                             BARC                                                                                                                                                                                                                                                                                                114                                        1558                                      1 year
  Mehran *et al* [@R2]                 30 days                             TIMI                                                                                                                                                                                                                                                                                                267                                        17 034                                    Up to 1 year
  Montalescot *et al* [@R25]           48 h                                STEEPLE                                                                                                                                                                                                                                                                                             3528 (total)                               NA                                        1 year
  Mrdovic *et al* [@R49]               Unclear                             TIMI                                                                                                                                                                                                                                                                                                22                                         2074                                      30 days and 1 year
  Musumeci *et al* [@R50]              30 days, 12 months, any follow-up   TIMI                                                                                                                                                                                                                                                                                                52                                         1385                                      3 years
  Ndrepepa *et al* [@R17]              Unclear                             REPLACE-2                                                                                                                                                                                                                                                                                           555                                        4015                                      1 year
  Ndrepepa *et al* [@R23]              In-hospital                         TIMI, REPLACE-2, BARC                                                                                                                                                                                                                                                                               Total 12 459                               NA                                        30 days, 1 year
  Pierre-Louis *et al* [@R51]          In-hospital                         Intracerebral or intraocular bleeding, clinical bleeding requiring blood transfusion, clinical bleeding with a reduction in haematocrit \>10 points, retroperitoneal or gastrointestinal bleeding, access site bleeding requiring intervention, and ≥4 cm diameter vascular access site haematoma   34                                         600                                       In-hospital
  Pilgrim and Wenaweser[@R52]          In-hospital                         TIMI                                                                                                                                                                                                                                                                                                48                                         3787                                      30 days
  Polanska-Skrzypczyk *et al* [@R53]   In-hospital                         TIMI                                                                                                                                                                                                                                                                                                40                                         1024                                      1 year
  Poludasu *et al* [@R54]              Unclear                             HORIZONS-AMI                                                                                                                                                                                                                                                                                        396                                        11 595                                    2.3 years
  Rao *et al* [@R24]                   Unclear                             GUSTO                                                                                                                                                                                                                                                                                               2908                                       23 544                                    Up to 6 months
  Rossini *et al* [@R55]               Unclear                             TIMI                                                                                                                                                                                                                                                                                                57                                         1301                                      1 year
  Urban *et al* [@R56]                 Unclear                             STEEPLE                                                                                                                                                                                                                                                                                             Total 15 147                               NA                                        360 days
  Valente *et al* [@R19]               In-hospital                         TIMI, ACUITY                                                                                                                                                                                                                                                                                        Total 991                                  NA                                        In-ICCU
  Yoon *et al* [@R57]                  In-hospital                         BARC type 2--5                                                                                                                                                                                                                                                                                      234                                        5932                                      2 years
  Zheng *et al* [@R58]                 Unclear                             TIMI                                                                                                                                                                                                                                                                                                27                                         385                                       1 year

ICCU, intensive coronary care unit; NA, not applicable; PCI, percutaneous coronary intervention.

Quality assessment {#s3c}
------------------

Online supplementary table S3 shows the quality assessment for included studies. Ascertainment of bleeding and mortality varied from data collection from medical record reviews to prospective evaluation in trials where independent committees adjudicated bleeding and outcome events.

### Major bleeding and risk of mortality at any time point {#s3c1}

The impact of major bleeding on mortality outcomes was studied in 40 studies reporting outcomes in 525 691 patients. In total, 66 016 major bleeds were reported. Crude rates or risk estimates for mortality in individual studies are shown in online supplementary table S4. Mortality rate was 3595/62 036 (5.8%, 28 studies) in patients who sustained a major bleed and 8937/370 522 (2.4%, 28 studies) in patients not experiencing major bleeding complications.

Meta-analysis of these data demonstrated that the overall risk of mortality was significantly greater among patients who sustained major bleeding complications periprocedurally ([figure 1](#OPENHRT2013000021F1){ref-type="fig"}). The risk estimate for mortality was significantly lower in the subgroup of studies, which adjusted for potential confounders (OR 3.31 (2.86 to 3.82), I^2^=80%, 491 565 participants compared to the OR calculated in those studies that did not adjust for baseline covariates; OR 6.75 (4.99 to 9.12), I^2^=62%, 34 126 participants).

![Adjusted risk of mortality with and without major bleed after percutaneous coronary intervention.](openhrt2013000021f01){#OPENHRT2013000021F1}

### Major bleeding and risk of MACEs at any time point {#s3c2}

The impact of major bleeding on MACEs outcomes was studied in 13 studies reporting outcomes in 69 843 patients. Crude rates or risk estimates for MACEs in individual studies are shown in [tables 3](#OPENHRT2013000021TB3){ref-type="table"} and [4](#OPENHRT2013000021TB4){ref-type="table"}; 757 major bleeds (6.8%) were reported.

###### 

Summary of risk of mortality and MACEs among patients with and without major bleed after percutaneous coronary intervention at different time points

  Duration                                                                              OR                    I^2^ (%)   Number of participants   Number of events in bleed group/total   Number of events in non-bleed group/total
  ------------------------------------------------------------------------------------- --------------------- ---------- ------------------------ --------------------------------------- -------------------------------------------
  Adjusted risk of mortality                                                                                                                                                              
   30 days[@R8] [@R14] [@R24] [@R28] [@R32] [@R36] [@R38] [@R39] [@R40] [@R41] [@R45]   3.24 (2.73 to 3.84)   81         403 457                  3307/59 630                             7645/317 375
   6 months[@R24] [@R27] [@R36] [@R42]                                                  3.23 (2.92 to 3.57)   0          50 872                   154/1028                                1119/20 606
   1 year[@R2] [@R22] [@R23] [@R25] [@R44] [@R48] [@R53] [@R56]                         3.64 (2.39 to 5.56)   89         74 637                   160/2494                                677/36 167
  Adjusted risk of MACEs                                                                                                                                                                  
   \<1 year[@R24] [@R34] [@R36]                                                         3.96 (3.26 to 4.81)   53         47 422                   175/790                                 1204/20 180
   \>1 year[@R43]                                                                       3.19 (1.89 to 5.38)   NA         3170                     NA                                      NA

MACEs, major adverse cardiovascular events; NA, not applicable.

###### 

Summary of risk of mortality and MACEs among patients with and without major bleed after percutaneous coronary intervention with different definitions of bleeding

  Mortality                                                                                             MACEs                                                                            
  ----------------------------------------------------------------------------------------------------- ---------------------- ---- --------- --------------- --------------------- ---- --------
  BARC[@R23] [@R38] [@R48]                                                                              5.40 (1.74 to 16.74)   88   14 550    BARC            NA                    NA   NA
  CRUSADE[@R33] [@R35] [@R45]                                                                           3.69 (1.68 to 8.12)    85   14 055    CRUSADE         NA                    NA   NA
  GUSTO[@R24] [@R40] [@R46]                                                                             4.30 (3.76 to 4.92)    0    27 222    GUSTO[@R24]     4.37 (3.78 to 5.07)   NA   26 452
  HORIZON-AMI[@R47] [@R54]                                                                              1.51 (1.11 to 2.05)    12   13 233    HORIZON-AMI     NA                    NA   NA
  REPLACE[@R17] [@R23] [@R34]                                                                           6.69 (2.26 to 19.81)   84   17 996    REPLACE         NA                    NA   NA
  STEEPLE[@R18] [@R25] [@R37] [@R43] [@R56]                                                             6.59 (3.89 to 11.16)   53   23 107    STEEPLE[@R43]   3.19 (1.89 to 5.37)   NA   3170
  TIMI[@R2] [@R8] [@R11] [@R19] [@R20] [@R21] [@R22] [@R42] [@R44] [@R49] [@R50] [@R52] [@R53] [@R55]   5.15 (4.01 to 6.61)    69   69 449    TIMI[@R21]      2.41 (1.42 to 4.35)   NA   1348
  Other[@R14] [@R27] [@R28] [@R32] [@R36] [@R39] [@R51]                                                 3.34 (2.59 to 4.32)    76   346 670   Other[@R36]     3.99 (3.3 to 4.82)    NA   19 622

MACEs, major adverse cardiovascular events; NA, not applicable.

MACE rates were 295/1701 (17.3%) in patients who sustained a major bleed and 2101/38 520 (5.4%) in patients not experiencing major bleeding complications. The overall risk of MACEs was significantly higher among patients with major bleeds ([figure 2](#OPENHRT2013000021F2){ref-type="fig"}). The risk of MACEs did not significantly differ in the subgroup of studies that adjusted for baseline covariates (OR 3.89 (3.26 to 4.64), I^2^=42%, 25 829 participants as compared to those that did not adjust for baseline covariates OR 3.12 (2.32 to 4.19), I^2^=52%, 101 184 participants).

![Adjusted risk of major adverse cardiovascular event with and without major bleed after percutaneous coronary intervention.](openhrt2013000021f02){#OPENHRT2013000021F2}

### Mortality with major bleeding at different follow-up durations {#s3c3}

The adjusted risk of mortality was significantly greater among patients with major bleeds at all time points evaluated ([figure 3](#OPENHRT2013000021F3){ref-type="fig"}). For 30-day mortality, adjusted risk was OR 3.24 (2.73 to 3.84, I^2^=81%, 11 studies, 403 457 participants) and at 6 months, the OR remained elevated at 3.23 (2.92 to 3.57, I^2^=0%, 4 studies, 50 872 participants; [table 3](#OPENHRT2013000021TB3){ref-type="table"}). At the 1-year time point, the risk of mortality was OR 3.64 (2.39 to 5.56, I^2^=89%, 9 studies).

![Risk of mortality with major bleed with different duration of follow-up.](openhrt2013000021f03){#OPENHRT2013000021F3}

### MACEs with bleeding at different follow-up durations {#s3c4}

Analysis of the impact of major bleeding on MACEs outcomes at different time points was stratified into risk of MACE \<1 year and ≥1 year due to the limited number of studies presenting MACE data and its relationship with time. The adjusted risk of MACE \<1 year was OR 3.96 (3.26 to 4.81, I^2^=53%, 2 studies, 47 422 participants) and for ≥1 year was OR 3.19 (1.89 to 5.37, 1 study, 3170 participants; [table 3](#OPENHRT2013000021TB3){ref-type="table"}).

### Adverse outcomes and different definitions for major bleeding {#s3c5}

The impact of different definitions of major bleeding on mortality and MACEs outcomes are presented in [table 4](#OPENHRT2013000021TB4){ref-type="table"}. REPLACE-2 (OR 6.69 (2.26 to 19.81), I^2^=84%, 3 studies, 17 996 participants) definition of major bleeding had the greatest impact on mortality outcomes, while the ACUITY/HORIZONS-AMI had the least impact (OR 1.51 (1.11 to 2.05), I^2^=12%, 1 study, 13 233 participants).

### Sensitivity analysis {#s3c6}

Sensitivity analysis excluding studies where not all participants had PCI did not significantly alter the pooled analysis for association between major bleeding and mortality (OR 3.16 (2.61 to 3.81), I^2^=75%, 372 449 participants).

Discussion {#s4}
==========

Advances in antithrombotic and antiplatelet therapy have improved outcomes following PCI through the reduction of ischaemic events although this has been at the expense of increased procedure-related bleeding complications. Our meta-analysis of 42 studies including over half a million patients confirms that major bleeding is independently associated with a threefold increase in mortality and MACEs outcomes, and that this increased mortality and MACEs risk observed following a major bleed is sustained for periods of over 1 year. We also show that major bleeding events as defined by different contemporary bleeding definitions have differential impacts on mortality outcomes, with 1.5--6.7-fold increases in mortality observed depending on the definition of major bleeding used.

There are a number of potential mechanisms that may underlie the relationship between major bleeding and adverse mortality outcomes. Patients that sustain major bleeding complications post PCI are more likely to be older, have renal failure, undergo PCI for STEMI/NSTEMI presentations, present with haemodynamic compromise or have a history of heart failure[@R2] [@R59] that also independently predict adverse mortality outcomes themselves. Many previous studies[@R17] that have reported on the prognostic impact of major bleeds have not accounted for differences in such baseline covariates that are themselves known to impact on mortality outcomes, which would overestimate the mortality risks associated with a major bleed. For example, in an analysis from the Global Registry of Acute Coronary Events (GRACE), major bleeding was no longer associated with 6-month mortality after adjustment for the known comorbidities with the authors concluding that comorbidities associated with major bleeding accounting for the higher rate of mortality in patients who bled.[@R15] Consistent with this, we have observed that in meta-analysis of studies that do not adjust for baseline covariates, major bleeding is associated with a sixfold increased risk in mortality, but this decreases to a threefold independent increase in mortality once baseline covariates are adjusted for, suggesting that major bleeding is independently linked to mortality and MACEs outcomes.

The potential mechanisms by which a major bleed adversely impacts on clinical outcomes are numerous. Major bleeds such as an intracranial haemorrhage or severe blood loss as can occur in a gastrointestinal haemorrhage may result in mortality directly, although such bleeding events would not explain the persistent mortality risk observed for over a year following a major bleeding event in our meta-analysis. Major bleeds may necessitate the discontinuation of antiplatelet or antithrombotic medications that increase the risk for stent thrombosis, a strong independent predictor of mortality outcomes in the short and longer term (\>1 year).[@R60] Furthermore, increased production of erythropoietin in response to anaemia that occurs following a major bleed may contribute to a prothrombotic systemic state beyond the acute phase through platelet activation and induction of plasminogen activator inhibitor-1 (PAI-1).[@R61] [@R62] Treatment with erythropoietin has been associated with increased risk of thrombosis in critical care patients[@R63] and increase in the composite endpoint of death, acute myocardial infarction, stroke and stent thrombosis in patients with STEMI.[@R64] Blood transfusions have been linked to adverse shorter and longer term mortality[@R65] and have been shown to predict 30-day mortality[@R66] independently of bleeding and haematocrit. Adverse mortality outcomes associated with blood transfusions occur through a number of mechanisms including prothrombotic effects mediated through acute platelet release of CD40 ligand,[@R67] platelet activation and induction of PAI-1[@R61] an inhibitor of endogenous fibrinolytic mechanisms. These increased risks of mortality also extend to non-red blood cell transfusions such as platelets or plasma/cryoprecipitate that may also be utilised following a periprocedural major bleed.[@R68]

Our observations of a differential impact of different major bleeding definitions on mortality outcomes is particularly pertinent suggesting that the choice of bleeding definition used has significantly influenced the outcome of previous studies, since the definition employed will influence the prevalence of reported bleeds as well as their prognostic impact. For example, in the RIVAL study[@R69] non-CABG related major bleeding as defined by the study was not significantly different between the radial and femoral arms of the study (OR=0.73, 95% CI 0.43 to 1.23; p=0.9), while use of the ACUITY major bleeding criterion was associated with a statistically significant reduction in major bleeding in the radial arm of the study (OR=0.43, 95% CI 0.32 to 0.57; p\<00001). Similarly, in the SYNERGY trial that used the GUSTO and TIMI major definition of bleeding, the enoxaparin arm was associated with a significantly higher rate of major bleeding as defined by TIMI major criteria but no difference in major bleeding as defined by the GUSTO major definition. Definitions that encompass less severe bleeding events (such as the ACUITY definition) are not as strongly linked to adverse events and therefore may not be a powerful means of evaluating bleeding avoidance strategies. In order to prove efficacy for bleeding avoidance the use of a more discriminative definition would be preferable.

Our meta-analysis has a number of potential limitations. First, an inherent limitation of any meta-analysis is that of publication bias; studies that show a neutral outcome in mortality are less likely to be published than those that show a positive outcome and thus tend to bias any meta-analysis of published data towards a more positive outcome. Second, studies included in this meta-analysis often used different antithrombotic and antiplatelet regimes for the PCI procedures undertaken for different indications, hence it is unclear whether the prognostic impact of a major bleed differs with different antiplatelet/anticoagulant combinations or whether it differs in the elective/acute coronary syndrome setting. Finally, our current analysis does not provide insight into whether the timing of the major bleed in relation to the index PCI procedure has a differential impact on mortality outcomes.

In conclusion, our meta-analysis of 42 studies including over half a million patients has revealed that major bleeding is independently associated with a threefold increase in mortality and MACEs outcomes, and that this increased mortality and MACEs risk observed following a major bleed is observed for periods of over 1 year. We also show that major bleeding events as defined by different contemporary bleeding definitions have differential impacts on mortality outcomes. Given the significant impact of major bleeding on mortality outcomes, formal bleeding risk assessment should be undertaken as part of the decision-making process for PCI procedures and bleeding avoidance strategies such as optimal pharmacotherapy and access site choice should be actively undertaken, particularly in those patients at highest baseline risk for bleeding complications.
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